Developer docs
API playgroundTry for free, no card

Search company profiles

Vibe Bio

Full company profile

uuid0002855

Namestring
Vibe Bio
Legal namestring
Vibe Biotechnology Inc.
Websiteurl
vibebio.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Vibe Bio is a Boston-based, remote-first company founded in 2021 by Alok Tayi, PhD, that operates a dual business combining an AI-powered SaaS platform for biopharma business development with a venture fund targeting rare and overlooked diseases. The company's core product, the VibeOne platform, uses natural language processing, predictive analytics, generative AI reasoning, and process automation to aggregate scientific, clinical, regulatory, and market data across more than 40 languages, then delivers expert-validated analyses that support go/no-go decisions on drug in-licensing and portfolio strategy for biopharma BD teams. Reported platform outcomes include 8x faster asset diligence, a 75% reduction in subject-matter expert workload, and 50% more assets identified globally, with particular emphasis on coverage of programs in China, Japan, and Korea.

The company sells VibeOne through a direct enterprise field-sales motion with quote-based annual subscription pricing and a "Request a demo" entry point, targeting Chief Strategy Officers and Business Development & Licensing executives at pharmaceutical and large biotech firms, as well as non-profit accelerators such as Orphan Therapeutics Accelerator. Complementing the platform business, Vibe Bio runs a venture fund that invests in and supports biotech founders developing platform technologies and therapeutics for rare diseases; disclosed portfolio companies include Eigen Therapeutics (priming therapies for cancer), Granata Bio (reproductive health, including its 2025 expansion to incorporate Oviva Therapeutics), and Cellular Intelligence (an AI-native TechBio that has raised over $60M from Khosla Ventures, CZI, SciFi VC, and AMD Ventures). The company also launches dedicated biotechs in partnership with patient foundations such as Chelsea's Hope and NF2 BioSolutions.

Vibe Bio launched publicly in June 2022 with $12M in seed financing led by Initialized Capital, alongside 6th Man Ventures, AlleyCorp, Arkitekt Ventures, Koa Labs, Lerer Hippeau, and Undeterred Capital. The company is registered as Vibe Biotechnology Inc. in Massachusetts, maintains a Scientific Advisory Board that includes Samuel Stupp (Northwestern), Kanya Rajangam (Senti Bio), and Yael Weiss (Mahzi Therapeutics), and continues to add roles across marketing, drug development, and engineering as it scales.

Short descriptiontext

Vibe Bio operates VibeOne, an AI-powered decision infrastructure platform that helps biopharma business development teams identify and evaluate drug assets globally, alongside a venture fund backing biotechs developing rare disease therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharma business development, AI drug discovery, drug asset diligence, rare disease therapeutics, biotech venture investing
Industry1 code
PRIMARYHLAGAJAL
Regulatory Information Management (RIM) & Submission Publishing Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Other Scientific and Technical Consulting Services54169
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharma AI Analytics Platform
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1VibeOne AI Platform - Business Development Services
TypeSubscription Recurring
Description

Expert-guided AI analysis platform for biopharma business development and licensing teams. The platform supports pipeline decisions with speed and discipline through subscription-based access to AI-powered asset identification, evaluation, and prioritization services.

vibebio.com
2Venture Fund Investment Returns
TypeLicensing Royalties
Description

Vibe Bio invests in founders developing platform technologies and therapeutics for rare and overlooked diseases. The venture fund generates returns through equity investments in portfolio companies including Eigen Therapeutics, Granata Bio, and Cellular Intelligence.

vibebio.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details1 tier
1Enterprise subscription model with custom pricing
ModelSubscriptionBilling cadenceAnnual
Notes

Pricing appears to be quote-based / not publicly disclosed. The company targets enterprise biopharma customers through direct sales engagement.

vibebio.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Vibe Bio operates the VibeOne AI platform, an enterprise decision infrastructure that helps biopharma business development and licensing teams identify, evaluate, and prioritize drug assets faster and with greater consistency. The platform aggregates global scientific, clinical, regulatory, and market data and applies AI reasoning combined with expert validation to deliver custom reports supporting go/no-go pipeline decisions. Complementing the platform, Vibe Bio operates a venture fund that invests in founders developing therapeutics for rare and overlooked diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 8x faster asset diligence with curated, aggregated, and centralized data
+3 more records
Product overview1 text field

Vibe Bio operates as a dual-entity company offering both an AI-powered SaaS platform and a venture fund. The core product is the VibeOne Platform—an AI decision infrastructure for biopharma business development that provides search, evaluation, and due diligence capabilities. This platform includes the VibeOne AI Analysis service (expert-guided AI analysis with data aggregation, pattern detection, and custom reporting) and the VibeOne Search & Evaluation module (for scanning drug landscapes and tracking competitive markets). Complementing the platform business, Vibe Bio operates a Venture Fund that invests in biotech founders targeting rare and overlooked diseases, applying the same VibeOne AI capabilities to guide portfolio decisions. The company was founded in 2021-2022 and is headquartered in Boston, MA.

Product and service2 records
1VibeOne Platform
CategoryBiopharma AI Analytics Software
Description

AI-powered decision infrastructure for biopharma business development that enables faster, better go/no-go pipeline decisions through automated asset identification, evaluation, and prioritization across indications, stages, and geographies. Sold via enterprise annual subscriptions to biopharma BD and licensing teams.

2Vibe Bio Venture Fund
CategoryBiotech Venture Capital
Description

Investment arm that provides funding and AI-driven due diligence and strategic support to biotech founders developing platform technologies and therapeutics, with particular emphasis on rare or overlooked diseases. Portfolio companies include Eigen Therapeutics, Granata Bio, and Cellular Intelligence.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-04-23
Description

Foundation focused on Lafora disease, a fatal form of progressive myoclonus epilepsy. Vibe Bio launched a biotech company in partnership with Chelsea's Hope.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Incite partnered with Vibe Bio to accelerate sarcoma drug discovery with unbiased ranking and AI-powered compound analysis. Vibe Bio provides AI analytics services for Incite's rare disease drug search and evaluation processes.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Non-profit biotech organization focused on completing development and commercializing therapies for ultra-rare conditions. Uses Vibe Bio for rare disease due diligence, pipeline and competitive analysis, and in-licensing strategy. OTXL announced foundational partnerships with rare disease-focused global biotech and pharmaceutical companies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Organization hoping to accelerate a gene therapy for neurofibromatosis Type 2. Vibe Bio launched a biotech company in partnership with NF2 BioSolutions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-powered platform focused on pharma asset identification, BD, and in-licensing signal generation. Most direct head-to-head competitor to VibeOne's use case of using AI to surface and prioritize drug programs for biopharma BD teams.

TypeDirect peer
Description

Biopharma deal intelligence and BD workflow platform used by pharma business development teams to source, evaluate, and track in-licensing opportunities. Comparable in target buyer (biopharma BD) and workflow (asset diligence) to VibeOne.

TypeBroad incumbent
Description

Large established provider of pharma intelligence, competitive intelligence, and BD analytics (e.g., Cortellis, Decision Resources Group). Competes with VibeOne for biopharma BD budgets at the portfolio strategy level, though as part of a much broader portfolio.

TypeBroad incumbent
Description

Global life sciences services and data analytics incumbent offering BD support, pipeline intelligence, and commercial diligence. Overlaps with VibeOne in BD analytics for biopharma but as one capability within a comprehensive CRO/data-services franchise.

TypeBroad incumbent
Description

Pharma pipeline, clinical trial, and deal intelligence provider (Pharmaprojects, Trialtrove). Directly comparable on the drug-asset visibility and pipeline benchmarking that VibeOne delivers, but as a content/data incumbent rather than an AI-native platform.

TypeEmerging player
Description

AI-native biotech combining proprietary data generation with ML for drug discovery and BD. Comparable on the AI-for-biopharma thesis and as a potential VibeOne customer/partner, though focused on internal pipeline rather than BD analytics as a service.

TypeEmerging player
Description

AI-driven drug discovery company applying ML to phenotypic and omics data. Comparable on AI-meets-biopharma positioning and target buyer overlap, though focused on its own pipeline development rather than BD decision infrastructure.

TypeEmerging player
Description

Cloud platform for life science R&D data and workflows. Adjacent rather than direct — same buyer (biopharma) but different use case (lab informatics vs. BD diligence) — and a plausible partner or substitute in a customer's AI/data stack.

TypeEmerging player
Description

AI platform applied to clinical research and drug development for biopharma partners. Comparable on AI-platform-for-biopharma model and enterprise GTM, though focused on clinical/ translational analytics rather than BD asset evaluation.

TypeEmerging player
Description

AI model of the human immune system for pharma R&D and pipeline prioritization. Comparable in selling AI-driven decision infrastructure to biopharma R&D and BD leadership, though focused on biological mechanism rather than deal sourcing.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vibe Bio

Biopharma AI Analytics Platformvibebio.com

Vibe Bio operates VibeOne, an AI-powered decision infrastructure platform that helps biopharma business development teams identify and evaluate drug assets globally, alongside a venture fund backing biotechs developing rare disease therapeutics.

What Vibe Bio does

Vibe Bio is a Boston-based, remote-first company founded in 2021 by Alok Tayi, PhD, that operates a dual business combining an AI-powered SaaS platform for biopharma business development with a venture fund targeting rare and overlooked diseases. The company's core product, the VibeOne platform, uses natural language processing, predictive analytics, generative AI reasoning, and process automation to aggregate scientific, clinical, regulatory, and market data across more than 40 languages, then delivers expert-validated analyses that support go/no-go decisions on drug in-licensing and portfolio strategy for biopharma BD teams. Reported platform outcomes include 8x faster asset diligence, a 75% reduction in subject-matter expert workload, and 50% more assets identified globally, with particular emphasis on coverage of programs in China, Japan, and Korea.

The company sells VibeOne through a direct enterprise field-sales motion with quote-based annual subscription pricing and a "Request a demo" entry point, targeting Chief Strategy Officers and Business Development & Licensing executives at pharmaceutical and large biotech firms, as well as non-profit accelerators such as Orphan Therapeutics Accelerator. Complementing the platform business, Vibe Bio runs a venture fund that invests in and supports biotech founders developing platform technologies and therapeutics for rare diseases; disclosed portfolio companies include Eigen Therapeutics (priming therapies for cancer), Granata Bio (reproductive health, including its 2025 expansion to incorporate Oviva Therapeutics), and Cellular Intelligence (an AI-native TechBio that has raised over $60M from Khosla Ventures, CZI, SciFi VC, and AMD Ventures). The company also launches dedicated biotechs in partnership with patient foundations such as Chelsea's Hope and NF2 BioSolutions.

Vibe Bio launched publicly in June 2022 with $12M in seed financing led by Initialized Capital, alongside 6th Man Ventures, AlleyCorp, Arkitekt Ventures, Koa Labs, Lerer Hippeau, and Undeterred Capital. The company is registered as Vibe Biotechnology Inc. in Massachusetts, maintains a Scientific Advisory Board that includes Samuel Stupp (Northwestern), Kanya Rajangam (Senti Bio), and Yael Weiss (Mahzi Therapeutics), and continues to add roles across marketing, drug development, and engineering as it scales.

Vibe Bio firmographics

Firmographics
Name
Vibe Bio
Legal name
Vibe Biotechnology Inc.
Website
https://vibebio.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Vibe Bio operates VibeOne, an AI-powered decision infrastructure platform that helps biopharma business development teams identify and evaluate drug assets globally, alongside a venture fund backing biotechs developing rare disease therapeutics.
Ownership category
akta.pro rank

Vibe Bio industry classification

Industry
Product category
Biopharma AI Analytics Platform
NAICS
Other Scientific and Technical Consulting Services (54169), Computer Systems Design and Related Services (54151)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAL
Regulatory Information Management (RIM) & Submission Publishing Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Biopharma business development
  • AI drug discovery
  • Drug asset diligence
  • Rare disease therapeutics
  • Biotech venture investing

Where Vibe Bio is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Vibe Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. VibeOne AI Platform - Business Development Services: Expert-guided AI analysis platform for biopharma business development and licensing teams. The platform supports pipeline decisions with speed and discipline through subscription-based access to AI-powered asset identification, evaluation, and prioritization services.
  2. Venture Fund Investment Returns: Vibe Bio invests in founders developing platform technologies and therapeutics for rare and overlooked diseases. The venture fund generates returns through equity investments in portfolio companies including Eigen Therapeutics, Granata Bio, and Cellular Intelligence.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise subscription model with custom pricing

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Vibe Bio product offering

Product offering

Core offering

Vibe Bio operates the VibeOne AI platform, an enterprise decision infrastructure that helps biopharma business development and licensing teams identify, evaluate, and prioritize drug assets faster and with greater consistency. The platform aggregates global scientific, clinical, regulatory, and market data and applies AI reasoning combined with expert validation to deliver custom reports supporting go/no-go pipeline decisions. Complementing the platform, Vibe Bio operates a venture fund that invests in founders developing therapeutics for rare and overlooked diseases.

Product overview

Vibe Bio operates as a dual-entity company offering both an AI-powered SaaS platform and a venture fund. The core product is the VibeOne Platform—an AI decision infrastructure for biopharma business development that provides search, evaluation, and due diligence capabilities. This platform includes the VibeOne AI Analysis service (expert-guided AI analysis with data aggregation, pattern detection, and custom reporting) and the VibeOne Search & Evaluation module (for scanning drug landscapes and tracking competitive markets). Complementing the platform business, Vibe Bio operates a Venture Fund that invests in biotech founders targeting rare and overlooked diseases, applying the same VibeOne AI capabilities to guide portfolio decisions. The company was founded in 2021-2022 and is headquartered in Boston, MA.

Differentiator

Problem solved

Functional benefit

Products and services

  • VibeOne Platform AI-powered decision infrastructure for biopharma business development that enables faster, better go/no-go pipeline decisions through automated asset identification, evaluation, and prioritization across indications, stages, and geographies. Sold via enterprise annual subscriptions to biopharma BD and licensing teams.
  • Vibe Bio Venture Fund Investment arm that provides funding and AI-driven due diligence and strategic support to biotech founders developing platform technologies and therapeutics, with particular emphasis on rare or overlooked diseases. Portfolio companies include Eigen Therapeutics, Granata Bio, and Cellular Intelligence.

Quantifiable outcome

  • 8x faster asset diligence with curated, aggregated, and centralized data
  • +3 more outcomes

Companies that use Vibe Bio

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Vibe Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature4 records

Vibe Bio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • Chelsea's HopeminorStrategic or Co-development Partner · 23 April 2025Foundation focused on Lafora disease, a fatal form of progressive myoclonus epilepsy. Vibe Bio launched a biotech company in partnership with Chelsea's Hope.
  • InciteminorStrategic or Co-development PartnerIncite partnered with Vibe Bio to accelerate sarcoma drug discovery with unbiased ranking and AI-powered compound analysis. Vibe Bio provides AI analytics services for Incite's rare disease drug search and evaluation processes.
  • Orphan Therapeutics AcceleratorcoreStrategic or Co-development PartnerNon-profit biotech organization focused on completing development and commercializing therapies for ultra-rare conditions. Uses Vibe Bio for rare disease due diligence, pipeline and competitive analysis, and in-licensing strategy. OTXL announced foundational partnerships with rare disease-focused global biotech and pharmaceutical companies.
  • NF2 BioSolutionsminorStrategic or Co-development PartnerOrganization hoping to accelerate a gene therapy for neurofibromatosis Type 2. Vibe Bio launched a biotech company in partnership with NF2 BioSolutions.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Vibe Bio competitors and assessment

Company assessment

Direct peers

  • InveniAI: AI-powered platform focused on pharma asset identification, BD, and in-licensing signal generation. Most direct head-to-head competitor to VibeOne's use case of using AI to surface and prioritize drug programs for biopharma BD teams.
  • DealForma: Biopharma deal intelligence and BD workflow platform used by pharma business development teams to source, evaluate, and track in-licensing opportunities. Comparable in target buyer (biopharma BD) and workflow (asset diligence) to VibeOne.

Broad incumbents

  • Clarivate: Large established provider of pharma intelligence, competitive intelligence, and BD analytics (e.g., Cortellis, Decision Resources Group). Competes with VibeOne for biopharma BD budgets at the portfolio strategy level, though as part of a much broader portfolio.
  • IQVIA: Global life sciences services and data analytics incumbent offering BD support, pipeline intelligence, and commercial diligence. Overlaps with VibeOne in BD analytics for biopharma but as one capability within a comprehensive CRO/data-services franchise.
  • Citeline (Pharma Intelligence): Pharma pipeline, clinical trial, and deal intelligence provider (Pharmaprojects, Trialtrove). Directly comparable on the drug-asset visibility and pipeline benchmarking that VibeOne delivers, but as a content/data incumbent rather than an AI-native platform.

Emerging players

  • Recursion Pharmaceuticals: AI-native biotech combining proprietary data generation with ML for drug discovery and BD. Comparable on the AI-for-biopharma thesis and as a potential VibeOne customer/partner, though focused on internal pipeline rather than BD analytics as a service.
  • Insitro: AI-driven drug discovery company applying ML to phenotypic and omics data. Comparable on AI-meets-biopharma positioning and target buyer overlap, though focused on its own pipeline development rather than BD decision infrastructure.
  • Benchling: Cloud platform for life science R&D data and workflows. Adjacent rather than direct — same buyer (biopharma) but different use case (lab informatics vs. BD diligence) — and a plausible partner or substitute in a customer's AI/data stack.
  • Owkin: AI platform applied to clinical research and drug development for biopharma partners. Comparable on AI-platform-for-biopharma model and enterprise GTM, though focused on clinical/ translational analytics rather than BD asset evaluation.
  • CytoReason: AI model of the human immune system for pharma R&D and pipeline prioritization. Comparable in selling AI-driven decision infrastructure to biopharma R&D and BD leadership, though focused on biological mechanism rather than deal sourcing.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Vibe Bio social profiles

Digital presence

Vibe Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vibe Bio leadership team

Management profile

Number of profiles

Profiles11 records

Vibe Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vibe Bio M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vibe Bio

What does Vibe Bio do?

Vibe Bio operates the VibeOne AI platform, an enterprise decision infrastructure that helps biopharma business development and licensing teams identify, evaluate, and prioritize drug assets faster and with greater consistency. The platform aggregates global scientific, clinical, regulatory, and market data and applies AI reasoning combined with expert validation to deliver custom reports supporting go/no-go pipeline decisions. Complementing the platform, Vibe Bio operates a venture fund that invests in founders developing therapeutics for rare and overlooked diseases.

Is Vibe Bio a public or private company?

Vibe Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vibe Bio founded?

Vibe Bio was founded in 2021. It employs 11 to 50 people.

Where is Vibe Bio based?

Vibe Bio is headquartered in Boston, United States, in the North America region.

How does Vibe Bio make money?

Two revenue lines are on record. VibeOne AI Platform - Business Development Services are the primary driver. The others are venture Fund Investment Returns.

Who are Vibe Bio's main competitors?

Direct peers on record are InveniAI and DealForma. Broad incumbents are Clarivate, IQVIA and Citeline (Pharma Intelligence). Emerging players are Recursion Pharmaceuticals, Insitro, Benchling, Owkin and CytoReason.

Does Vibe Bio have an API?

No public API is recorded for Vibe Bio.

What industry is Vibe Bio in?

Vibe Bio's product category is Biopharma AI Analytics Platform. Its primary akta.pro industry code is HLAGAJAL, Regulatory Information Management (RIM) & Submission Publishing Software. Its NAICS code is 54169 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YellowYellow.comThe article provides an overview of Decentralized Science (DeSci), a movement leveraging blockchain and Web3 technologies to democratize scientific research by addressing funding inequities, publication barriers, and accessibility issues. Key projects such as Molecule, VitaDAO, LabDAO, Vibe Bio, and AntidoteDAO are highlighted for their roles in creating decentralized infrastructure for funding, governance, and data storage. The sector is experiencing rapid growth, with approximately half of tracked projects launched in the past year, though it still faces challenges regarding technological complexity and institutional adoption.The BlockAlok Tayi, Co-Founder & CEO, Vibe BioVibe Bio, co-founded by Alok Tayi, raised $12 million in a funding round led by Initialized Capital. The biotech startup uses a decentralized autonomous organization (DAO) to let patients and token holders vote on funding rare-disease treatments. The company aims to disrupt centralized biotech financing.FinSMEsVibe Bio Raises $12M in FundingBoston-based biotechnology company Vibe Bio raised $12 million in funding led by Initialized Capital to scale the development of treatments for rare diseases. The funds will support its decentralized autonomous organization (DAO) model, which allows patient communities to vote on research proposals via a governance token. The company has already partnered with patient advocacy groups to launch independent entities, New Hope Therapeutics and Merlin Therapeutics, for specific rare disease research.